drugset
drugset / Trial / NCT02665702

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

NCT02665702 ↗

Phase 2 Unknown 76 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

Timeline

Start
2016-01
Primary completion
2018-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject DDP Unknown 25 mg/m2 —
Subject DDP Unknown 75 mg/m2 —
Subject Endostar Protein / enzyme biologic 15 mg —
Subject NVB Unknown 25 mg/m2 —

Indications

esophageal squamous cell carcinoma